Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in New Jersey
9 open options
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALPHASE2RECRUITING
Exercise to Improve Brain Health in Older African Americans
Cardio-Dance Fitness · Strength, Flexibility & Balance — 1 site
- TRIALNAENROLLING_BY_INVITATION
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Sensory Stimulation System (GS120) - Active — 53 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT · KarX-EC · Placebo — 126 sites
- TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.